On April 15, Bayer announced that its innovative targeted therapy Hyrnuo® (sevabertinib, BAY 2927088) has been officially approved by the National Medical Products Administration. ✨ This milestone marks sevabertinib approved in China for HER2-mutant NSCLC,…
On March 27, 2026, the National Medical Products Administration (NMPA) of China officially approved GSK Exdensur (depemokimab) in China for marketing. The approval covers maintenance treatment of adults and adolescents aged 12 years and older…
The ABSK061 achondroplasia orphan drug designation marks an important regulatory milestone in the development of targeted therapies for rare genetic skeletal disorders. Developed by Abbisko Therapeutics, ABSK061 is a selective FGFR2/3 inhibitor designed to target…
In February 2026, several new cancer drugs approved by global regulatory authorities marked significant progress in oncology treatment. These approvals came from organizations including China’s National Medical Products Administration (NMPA), the U.S. Food and Drug…
According to the National Medical Products Administration (NMPA), three innovative drugs were approved for marketing in China in February 2026. These newly added entries to the NMPA approved drugs list cover moderate-to-severe plaque psoriasis, myelofibrosis,…
In May 2023, China’s National Medical Products Administration (NMPA) approved the first domestically developed generic version of olaparib tablets. Developed by Qilu Pharmaceutical, this olaparib product was officially approved on May 12 and subsequently launched…
Adebrelimab approval in China marks a significant milestone in the country’s oncology landscape. In 2023, China’s National Medical Products Administration (NMPA) approved adebrelimab injection (Airuili®) for use in combination with standard chemotherapy as a first-line…
As innovation in drug research and development continues to accelerate, the pharmaceutical industry is entering a new stage of evolution. By 2026, competition is no longer defined solely by the ability to innovate but increasingly…
In the era of precision oncology, an effective treatment strategy requires more than just a powerful therapeutic “weapon.” It also depends on a flexible “delivery system” and adaptable “tactics” tailored to different clinical scenarios. The…
(China, December 23, 2025) — Sunshine Guojian Pharmaceutical, a leading biopharmaceutical company in China, today announced that TPIAO approved for a new indication—its independently developed Class 1 innovative drug—by the National Medical Products Administration (NMPA).…
On January 6, 2026, BeiGene (Suzhou) Biotech Co., Ltd. (BeiGene) ‘s independently developed innovative drug Sonrotoclax tablets (trade name: Baiyueda®) were officially approved for market launch in China. The approved indications for sonrotoclax tablets in China…
On December 25, 2020, the National Medical Products Administration (NMPA) granted priority review and approval for orelabrutinib tablets (brand name: InnoCare®), a Class 1 innovative drug independently developed by Beijing InnoCare Pharma Technology Co., Ltd.…
